Critical Care & Emergencies (all articles)
Perspective | COVID-19: The rise and rise of Delta.
22 Jun, 2021 | 10:10h | UTCCOVID-19: The rise and rise of Delta – Sciblogs
Case report: Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection.
22 Jun, 2021 | 10:04h | UTC
M-A: Azithromycin does not reduce the need for invasive mechanical ventilation or mortality in patients with Covid-19.
21 Jun, 2021 | 08:45h | UTC
Consensus-based recommendations for management of the difficult airway: part 1. Difficult airway management encountered in an unconscious patient.
21 Jun, 2021 | 08:33h | UTC
RCT: Routine use of prophylactic postoperative continuous positive airway pressure (CPAP) does not prevent pneumonia, re-intubation, and death after major abdominal surgery.
21 Jun, 2021 | 08:32h | UTCPostoperative continuous positive airway pressure to prevent pneumonia, re-intubation, and death after major abdominal surgery (PRISM): a multicentre, open-label, randomised, phase 3 trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter (thread – click for more)
Published today in @LancetRespirMed is the final report of @prismtrial, an international multi-centre phase-3 randomised trial of routine postoperative CPAP to prevent pneumonia, re-intubation & death after major abdominal surgery https://t.co/e09pSTi2sa @rupert_pearse @QMULWHRI
— Tom Abbott (@_tomabbott) June 19, 2021
Cohort study: swallowing and voice outcomes in patients hospitalized with COVID-19.
18 Jun, 2021 | 08:24h | UTCRelated study: Characterization of dysphagia and laryngeal findings in COVID-19 patients treated in the ICU—An observational clinical study – PLOS One
ECMM/ISHAM recommendations for clinical management of COVID -19 associated mucormycosis in low- and middle-income countries.
18 Jun, 2021 | 08:26h | UTC
Study commentary: a history of hypothermia for cardiac arrest, 2002-2021 (RIP).
18 Jun, 2021 | 08:20h | UTCA history of hypothermia for cardiac arrest, 2002-2021 (RIP) – PulmCrit
Original study: RCT: In patients with coma after out-of-hospital cardiac arrest, targeted hypothermia did not improve outcomes.
Commentary on Twitter
A history of hypothermia for cardiac arrest, 2002-2021 (RIP)🪦
🥶2002 studies supporting hypothermia were weak
🥶robust studies refute benefit (TTM1 & TTM2)
🥶growing evidence of iatrogenic harm
🥶post-arrest hypothermia should be restricted to within RCTshttps://t.co/GZbpgHXWoD pic.twitter.com/ILUAiqqLQl— 𝙟𝙤𝙨𝙝 𝙛𝙖𝙧𝙠𝙖𝙨 💊 (@PulmCrit) June 17, 2021
[Preprint] RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalized COVID-19 patients who have not mounted their own immune response.
17 Jun, 2021 | 09:55h | UTCOriginal study (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv
Commentaries: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients – Science AND Antibody combo cuts COVID deaths by 20% in very ill seronegative patients – CIDRAP AND Regeneron antibody saves lives in some hospitalized Covid patients, study finds – STAT AND Expert reaction to press release from the RECOVERY trial reporting that Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response – Science Media Centre
Commentary on Twitter
RECOVERY Pre-print:
In patients hospitalised with COVID-19 but no natural antibody response, monoclonal antibody infusion:
– reduced mortality
– increased speed of discharge
– reduced progression to invasive mechanical ventilation or deathhttps://t.co/rpDk4eUhmm pic.twitter.com/wXegKcDZg8— Martin Landray (@MartinLandray) June 16, 2021
RCT: Tofacitinib reduced the risk of death or respiratory failure in patients hospitalized with Covid-19 pneumonia.
17 Jun, 2021 | 09:58h | UTCTofacitinib in Patients Hospitalized with Covid-19 Pneumonia – New England Journal of Medicine
Commentary on Twitter:
Patients who were hospitalized with #COVID19 pneumonia were randomly assigned, at a median of 10 days after symptom onset, to receive tofacitinib or placebo. At 28 days, the risk of death or respiratory failure was lower in the tofacitinib group. #IDTwitter
— NEJM (@NEJM) June 16, 2021
Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination.
17 Jun, 2021 | 09:43h | UTCCommentary: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology
Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
CDC now calls coronavirus Delta variant a ‘variant of concern’.
17 Jun, 2021 | 09:53h | UTCCDC now calls coronavirus Delta variant a ‘variant of concern’ – CNN
Guidance: SARS-CoV-2 Variant Classifications and Definitions – Centers for Disease Control and Prevention
Commentary on Twitter
BREAKING—CDC now officially declares #DeltaVariant a “variant of concern”—because much more transmissible (50% faster than #B117, 2x than original strain), more severe (2.5x hospitalization risk than B117, 4x original) & 1 dose vaccine evasive.🧵 #COVID19https://t.co/jZCgfzFLla pic.twitter.com/SszvXuysze
— Eric Feigl-Ding (@DrEricDing) June 15, 2021
Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination.
17 Jun, 2021 | 09:45h | UTCMyocarditis after BNT162b2 and mRNA-1273 Vaccination – Circulation
Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
RCT: In patients with coma after out-of-hospital cardiac arrest, targeted hypothermia did not improve outcomes.
17 Jun, 2021 | 09:39h | UTCNews release: Induced hypothermia after cardiac arrest did not improve survival – Lund University
Infographic: The TTM2 Trial – CanadianEM
Commentary: Hypothermia or Normothermia after Cardiac Arrest – NEJM Resident 360
Video: TTM2 Results Presentation Livestream – Critical Care Reviews
Commentary on Twitter (thread – click for more)
The #TTM2trial was published today in the @NEJM https://t.co/jccLB1MO64
Here’s a summary of what we did, what I think the trial means, and what next.@ttm2trial @nielsen_niklas @CritCareReviews @NEJM— Paul Young (@DogICUma) June 16, 2021
Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination.
17 Jun, 2021 | 09:41h | UTCRelated: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
M-A: Extracorporeal membrane oxygenation for COVID-19.
16 Jun, 2021 | 08:22h | UTC
AHA Scientific Statement: Mechanical Complications of Acute Myocardial Infarction.
16 Jun, 2021 | 08:21h | UTC
SARS-CoV-2 Delta variant in Scotland: demographics, risk of hospital admission, and vaccine effectiveness – “Risk of COVID-19 hospital admission was approximately doubled in those with the Delta VOC when compared to the Alpha VOC”.
15 Jun, 2021 | 09:10h | UTCCommentaries: Delta may raise hospitalisation but vaccine still protects – UK Research and Innovation AND Expert reaction to Lancet research letter analysing data from Scotland on the Delta variant, looking at demographics, risk of hospital admission and vaccine effectiveness – Science Media Centre
Commentary on Twitter (thread – click for more)
Just published @TheLancet
The #DeltaVariant experience in Scotlandhttps://t.co/IfjDJnCAMC
1. #VaccinesWork ("AZ appeared less effective than Pfizer")
2. Younger, unvaccinated got the delta infections
3. Doubling of hospital admissions compared with alpha (B.1.1.7) variant pic.twitter.com/cP8clu57Rd— Eric Topol (@EricTopol) June 14, 2021
Delta variant producing more severe illness, doctors in China say.
15 Jun, 2021 | 09:02h | UTCIn China’s latest outbreak, doctors say the infected get sicker, faster. – The New York Times (a few articles per month are free)
A new coronavirus variant (Delta) is on the rise. Here’s why experts are concerned.
15 Jun, 2021 | 09:03h | UTCA new coronavirus variant is on the rise. Here’s why experts are concerned – CNN
Systematic review: Endovascular thrombectomy and intra‐arterial interventions for acute ischemic stroke – “In individuals with acute ischemic stroke due to large artery occlusion in the anterior circulation, endovascular thrombectomy can increase the chance of survival with a good functional outcome”.
15 Jun, 2021 | 08:56h | UTCSummary: Endovascular thrombectomy for acute ischaemic stroke – Cochrane Library
RCT: No difference in 30-day mortality with discontinuation vs. continuation of renin-angiotensin-system inhibitors in patients with COVID-19, but secondary and explorative analysis showed discontinuation of RAS-inhibition may lead to a faster and better recovery.
14 Jun, 2021 | 08:47h | UTCEditorial: RAS inhibition and COVID-19: more questions than answers?
Related randomized trials showing no benefit from discontinuation: Randomized trial: No benefit from discontinuing ACE Inhibitors and ARBs in patients admitted with COVID-19 AND Randomized trial: Renin–angiotensin system inhibitors can be safely continued in patients admitted to hospital with COVID-19
M-A: Effect of ultrashort-acting betablockers on mortality in patients with sepsis with persistent tachycardia.
14 Jun, 2021 | 08:33h | UTC
ESC Consensus Document: Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions.
14 Jun, 2021 | 08:31h | UTCCommentaries: Periprocedural MIs Associated With PCI Prognostically Relevant: ESC/EAPCI – TCTMD AND Periprocedural Myocardial Injury and MI Associated With PCI – American College of Cardiology
M-A: No difference in major postoperative complications or mortality with perioperative liberal vs. restrictive fluid strategies in major abdominal elective surgery.
14 Jun, 2021 | 08:30h | UTC